Please assess the completion status of the following clinical trial:

Trial Title: Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion criteria:~* Histologically documented marginal zone lymphoma including splenic, nodal, and extranodal sub-types; subjects with splenic MZL must have an additional measurable lesion, nodal or extranodal, as described in inclusion criteria 5~* Previously received one or more lines of therapy including at least one CD20-directed regimen (either as monotherapy or as chemoimmunotherapy) with documented failure to achieve at least PR or documented PD after, the most recent systemic treatment regimen~* Men and women ≥18 years of age~* ECOG performance status of ≤2~* ≥1 measurable lesion site on CT scan (\>1.5 cm in longest dimension). Lesions in anatomical locations (such as extremities or soft tissue lesions) that are not well visualized by CT may be measured by MRI instead. (Subjects with spleen-only disease are considered as not having measurable disease.)~* Life expectancy of \>3 months, in the opinion of the investigator~Key Exclusion criteria:~* Medically apparent CNS lymphoma or leptomeningeal disease~* History of other malignancies except adequately treated non melanoma skin cancer, curatively treated in-situ cancer, or other solid tumors curatively treated with no evidence of disease for ≥2 years~* History of allogeneic stem-cell (or other organ) transplantation~* Any chemotherapy, anticancer antibodies, or other systemic anticancer therapy within 21 days of the first dose of study drug~* Any external beam radiation therapy within 6 weeks prior to the first dose of the study drug~* Concurrent use of warfarin or other vitamin K antagonists~* Concurrent use of a strong CYP3A inhibitor. Subjects who have received a strong CYP3A inhibitor prior to entering the study must have discontinued therapy for at least 5 half lives of the prohibited medication.~* Recent infection requiring IV anti-infective treatment that was completed ≤14 days before the first dose of study drug~* Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to CTCAE Grade 0 or 1, or to the levels dictated in the eligibility criteria with the exception of alopecia~* Inadequate organ function as defined on laboratory tests

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ibrutinib (Type: EXPERIMENTAL): ibrutinib capsules: 560 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).